319 related articles for article (PubMed ID: 23620213)
1. Productivity costs in economic evaluations: past, present, future.
Krol M; Brouwer W; Rutten F
Pharmacoeconomics; 2013 Jul; 31(7):537-49. PubMed ID: 23620213
[TBL] [Abstract][Full Text] [Related]
2. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects.
Krol M; Brouwer WB; Severens JL; Kaper J; Evers SM
Soc Sci Med; 2012 Dec; 75(11):1981-8. PubMed ID: 22925428
[TBL] [Abstract][Full Text] [Related]
3. How to estimate productivity costs in economic evaluations.
Krol M; Brouwer W
Pharmacoeconomics; 2014 Apr; 32(4):335-44. PubMed ID: 24504850
[TBL] [Abstract][Full Text] [Related]
4. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses.
Bouwmans C; Krol M; Severens H; Koopmanschap M; Brouwer W; Hakkaart-van Roijen L
Value Health; 2015 Sep; 18(6):753-8. PubMed ID: 26409601
[TBL] [Abstract][Full Text] [Related]
5. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective.
Hubens K; Krol M; Coast J; Drummond MF; Brouwer WBF; Uyl-de Groot CA; Hakkaart-van Roijen L
Value Health; 2021 Nov; 24(11):1686-1699. PubMed ID: 34711370
[TBL] [Abstract][Full Text] [Related]
6. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review.
Kigozi J; Jowett S; Lewis M; Barton P; Coast J
Value Health; 2017 Mar; 20(3):496-506. PubMed ID: 28292496
[TBL] [Abstract][Full Text] [Related]
7. Measuring and valuing productivity loss due to poor health: A critical review.
Zhang W; Bansback N; Anis AH
Soc Sci Med; 2011 Jan; 72(2):185-92. PubMed ID: 21146909
[TBL] [Abstract][Full Text] [Related]
8. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.
Brouwer WB; Koopmanschap MA; Rutten FF
Health Econ; 1997; 6(3):253-9. PubMed ID: 9226143
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluations of occupational health interventions from a company's perspective: a systematic review of methods to estimate the cost of health-related productivity loss.
Uegaki K; de Bruijne MC; van der Beek AJ; van Mechelen W; van Tulder MW
J Occup Rehabil; 2011 Mar; 21(1):90-9. PubMed ID: 20668923
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?
Jones C; Verstappen SMM; Payne K
Appl Health Econ Health Policy; 2019 Oct; 17(5):591-613. PubMed ID: 30937837
[TBL] [Abstract][Full Text] [Related]
11. Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.
Yuasa A; Yonemoto N; LoPresti M; Ikeda S
Pharmacoeconomics; 2021 Jan; 39(1):81-97. PubMed ID: 33230613
[TBL] [Abstract][Full Text] [Related]
12. Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.
Pike J; Grosse SD
Appl Health Econ Health Policy; 2018 Dec; 16(6):765-778. PubMed ID: 30094591
[TBL] [Abstract][Full Text] [Related]
13. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
Her M; Kavanaugh A
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
[TBL] [Abstract][Full Text] [Related]
14. Design of a trial-based economic evaluation on the cost-effectiveness of employability interventions among work disabled employees or employees at risk of work disability: the CASE-study.
Noben CY; Nijhuis FJ; de Rijk AE; Evers SM
BMC Public Health; 2012 Jan; 12():43. PubMed ID: 22257557
[TBL] [Abstract][Full Text] [Related]
15. Variation in the methodological approach to productivity cost valuation: the case of prostate cancer.
Hanly P; Maguire R; Drummond F; Sharp L
Eur J Health Econ; 2019 Dec; 20(9):1399-1408. PubMed ID: 31444674
[TBL] [Abstract][Full Text] [Related]
16. [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].
Merkesdal S; Huelsemann JL; Mittendorf T; Zeh S; Zeidler H; Ruof J
Z Rheumatol; 2006 Oct; 65(6):527-34. PubMed ID: 16534538
[TBL] [Abstract][Full Text] [Related]
17. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
Knies S; Severens JL; Ament AJ; Evers SM
Value Health; 2010 Aug; 13(5):519-27. PubMed ID: 20712601
[TBL] [Abstract][Full Text] [Related]
18. Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.
Yuasa A; Yonemoto N; Kamei K; Murofushi T; LoPresti M; Taneja A; Horgan J; Ikeda S
Adv Ther; 2022 Dec; 39(12):5327-5350. PubMed ID: 36205907
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
[TBL] [Abstract][Full Text] [Related]
20. Indirect costs and public finance consequences of heart failure in Poland, 2012-2015.
Łyszczarz B
BMC Public Health; 2018 Sep; 18(1):1130. PubMed ID: 30231932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
